{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:55:44Z","timestamp":1782777344279,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03704-w","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T07:02:40Z","timestamp":1726038160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The risk of thromboembolic events in patients with nephrotic syndrome and relatively high albumin levels: a study over 10\u00a0years"],"prefix":"10.1186","volume":"25","author":[{"given":"Yi-meng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"2","key":"3704_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","volume":"117","author":"BK Mahmoodi","year":"2008","unstructured":"Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.716951.","journal-title":"Circulation"},{"issue":"45","key":"3704_CR2","first-page":"100","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2021;100(45):100\u20133 128,138.","journal-title":"Kidney Int"},{"issue":"1","key":"3704_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/ndt\/gfw227","volume":"32","author":"G Gyamlani","year":"2017","unstructured":"Gyamlani G, Molnar MZ, Lu JL, et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32(1):157\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfw227.","journal-title":"Nephrol Dial Transplant"},{"key":"3704_CR4","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.12659\/msm.896090","volume":"22","author":"X Li","year":"2016","unstructured":"Li X, Wei D, Zhou Z, et al. Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy. Med Sci Monit. 2016;22:1630\u20136. https:\/\/doi.org\/10.12659\/msm.896090.","journal-title":"Med Sci Monit"},{"issue":"3","key":"3704_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513\u201320. https:\/\/doi.org\/10.2215\/CJN.10131011.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3704_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.2011.312","volume":"81","author":"SJ Barbour","year":"2012","unstructured":"Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190\u20135. https:\/\/doi.org\/10.1038\/ki.2011.312.","journal-title":"Kidney Int"},{"issue":"5","key":"3704_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","volume":"89","author":"T Lee","year":"2016","unstructured":"Lee T, Derebail VK, Kshirsagar AV, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111\u20138. https:\/\/doi.org\/10.1016\/j.kint.2015.12.041.","journal-title":"Kidney Int"},{"issue":"6","key":"3704_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","volume":"25","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357\u201366. https:\/\/doi.org\/10.1681\/ASN.2013040430.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3704_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/0886022X.2022.2057861","volume":"44","author":"H Zhu","year":"2022","unstructured":"Zhu H, Xu L, Liu X, et al. Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy. Ren Fail. 2022;44(1):594\u2013600. https:\/\/doi.org\/10.1080\/0886022X.2022.2057861.","journal-title":"Ren Fail"},{"key":"3704_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574997","volume":"11","author":"M Cremoni","year":"2020","unstructured":"Cremoni M, Brglez V, Perez S, et al. Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses. Front Immunol. 2020;11: 574997. https:\/\/doi.org\/10.3389\/fimmu.2020.574997.","journal-title":"Front Immunol"},{"issue":"5","key":"3704_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrneph.2014.38","volume":"10","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10(5):279\u201389. https:\/\/doi.org\/10.1038\/nrneph.2014.38.","journal-title":"Nat Rev Nephrol"},{"key":"3704_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3389\/fimmu.2018.01008","volume":"9","author":"A Turrent-Carriles","year":"2018","unstructured":"Turrent-Carriles A, Herrera-F\u00e9lix JP, Amigo MC. Renal Involvement in Antiphospholipid Syndrome. Front Immunol. 2018;9:1008. https:\/\/doi.org\/10.3389\/fimmu.2018.01008.","journal-title":"Front Immunol"},{"issue":"2-3","key":"3704_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000206027","volume":"76","author":"S Sukenik","year":"1986","unstructured":"Sukenik S, el-Roeiy A, Shoenfeld Y. Lupus anticoagulant and anticardiolipin antibodies in systemic lupus erythematosus. Acta Haematol. 1986;76(2\u20133):86\u20139. https:\/\/doi.org\/10.1159\/000206027.","journal-title":"Acta Haematol"},{"issue":"6398","key":"3704_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/bmj.287.6398.1021","volume":"287","author":"ML Boey","year":"1983","unstructured":"Boey ML, Colaco CB, Gharavi AE, et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287(6398):1021\u20133. https:\/\/doi.org\/10.1136\/bmj.287.6398.1021.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"3704_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","volume":"20","author":"S Kelddal","year":"2019","unstructured":"Kelddal S, Nykj\u00e6r KM, Gregersen JW, et al. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol. 2019;20(1):139. https:\/\/doi.org\/10.1186\/s12882-019-1336-8.","journal-title":"BMC Nephrol"},{"issue":"6","key":"3704_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/ki.2013.476","volume":"85","author":"T Lee","year":"2014","unstructured":"Lee T, Biddle AK, Lionaki S, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 2014;85(6):1412\u201320. https:\/\/doi.org\/10.1038\/ki.2013.476.","journal-title":"Kidney Int"},{"issue":"4","key":"3704_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","volume":"3","author":"DJ Sexton","year":"2018","unstructured":"Sexton DJ, de Freitas DG, Little MA, et al. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome. Kidney Int Rep. 2018;3(4):784\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2018.02.010.","journal-title":"Kidney Int Rep"},{"key":"3704_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002770000163","volume":"79","author":"M Feuring-Buske","year":"2000","unstructured":"Feuring-Buske M, Kneba M, Unterhalt M, et al. IDECC2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493\u2013500. https:\/\/doi.org\/10.1007\/s002770000163.","journal-title":"Ann Hematol"},{"issue":"1","key":"3704_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1078155214543278","volume":"22","author":"R Dada","year":"2016","unstructured":"Dada R, Zekri J, Ramal B, et al. Acute jugular vein thrombosis during rituximab administration: Review of the literature. J Oncol Pharm Pract. 2016;22(1):165\u20139. https:\/\/doi.org\/10.1177\/1078155214543278.","journal-title":"J Oncol Pharm Pract"},{"key":"3704_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/rheumatology\/ken4","volume":"48","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Nagaswa H, Kameda H, et al. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I\/II clinical trial for refractory systemic lupus erythematosus. Rheumatology. 2009;48:198\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/ken4.","journal-title":"Rheumatology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03704-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T07:06:26Z","timestamp":1726038386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03704-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3704"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03704-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and has been granted an exemption from requiring written informed consent by Peking University First Hospital Clinical Research Ethics Committee. (2023\u2013741).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}